Zhang Jiarui, Zou Haitao, Tang Yongjiang, Peng Lige, Pu Jiaqi, Zeng Jiaxin, Chen Xueqing, Yuan Jianlin, Yi Qun, Zhou Haixia
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Guo-xue-xiang 37#, Wuhou District, Chengdu, 610041, Sichuan Province, China.
Department of Respiratory and Critical Care Medicine, Dianjiang People's Hospital of Chongqing, Chongqing Province, China.
Sci Rep. 2024 Dec 3;14(1):30038. doi: 10.1038/s41598-024-81520-w.
Evidence for the prognostic impact of chest pain in acute pulmonary embolism (APE) is limited. This study aimed to assess the prognostic value of chest pain in a Chinese cohort of patients with APE. Consecutive hospitalized patients diagnosed with APE between January 2016 and December 2019 were retrospectively enrolled and followed prospectively for 2 years at West China Hospital of Sichuan University. The primary outcome was in-hospital all- cause mortality, while the secondary outcomes included 3-month, 6-month, and 2-year all-cause mortality, APE recurrence, mechanical ventilation, and length of hospital stay (LOS). A total of 737 APE patients met the study criteria, with 254 patients (34.5%) presented with chest pain at admission. Patients with chest pain had significantly lower in-hospital (3.1% vs. 11.2%), 3-month (3.7% vs. 7.5%), 6-month (5.3% vs. 10.0%), and 2-year (9.8% vs. 15.4%) all-cause mortality compared to patients without chest pain (all P < 0.05). A lower rate of mechanical ventilation was observed in APE patients with chest pain, and no significant differences were identified in terms of APE recurrence and LOS between APE patients with and without chest pain. Chest pain was an independent predictor of in-hospital mortality in three separate multivariable models (range of odds ratios 0.390-0.423, all P < 0.05). APE patients with chest pain had a lower short-term and long-term all-cause mortality compared to those without chest pain. Chest pain may be considered a strong, favorable prognostic marker in acute pulmonary embolism.
胸痛对急性肺栓塞(APE)预后影响的证据有限。本研究旨在评估胸痛在中国APE患者队列中的预后价值。回顾性纳入了2016年1月至2019年12月期间在四川大学华西医院连续住院诊断为APE的患者,并对其进行了为期2年的前瞻性随访。主要结局是住院全因死亡率,次要结局包括3个月、6个月和2年全因死亡率、APE复发、机械通气及住院时间(LOS)。共有737例APE患者符合研究标准,其中254例(34.5%)入院时出现胸痛。与无胸痛的患者相比,有胸痛的患者住院(3.1%对11.2%)、3个月(3.7%对7.5%)、6个月(5.3%对10.0%)和2年(9.8%对15.4%)的全因死亡率均显著降低(所有P<0.05)。有胸痛的APE患者机械通气率较低,在有无胸痛的APE患者之间,APE复发和LOS方面未发现显著差异。在三个独立的多变量模型中,胸痛是住院死亡率的独立预测因素(比值比范围为0.390 - 0.423,所有P<0.05)。与无胸痛的患者相比,有胸痛的APE患者短期和长期全因死亡率较低。胸痛可被视为急性肺栓塞中一个强有力的、良好的预后标志物。